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The World Health Organization (WHO) has re-
cently announced that the global phenomenon
of antimicrobial resistance will be the theme of
World Health Day 2011.1 The campaign, which
aims to safeguard medicines for future genera-
tions, will call on governments around the world
to implement policies to prevent the emergence
of highly resistant “superbugs”.1,2
Asia remains the epicenter of resistant super-
bugs.3,4 In Taiwan, there is an alarmingly high
prevalence of penicillin-resistant Streptococcus
pneumoniae, community-acquired and hospital-
acquired methicillin-resistant Staphylococcus aureus
(MRSA), extended-spectrum β-lactamase-produc-
ing Escherichia coli and Klebsiella pneumoniae,
multidrug-resistant and extensively drug-resistant
Pseudomonas aeruginosa and Acinetobacter baumannii,
as well as penicillin- and fluoroquinolone-resistant
Neisseria gonorrhoeae. Fluoroquinolone-resistant
E coli and Salmonella species, particularly S enterica
serotype Choleraesuis, are found not only in hu-
mans but also in animals. Azole-resistant Candida
species, especially C glabrata, are prevalent in
hospitals throughout Taiwan.3,4 In addition, the
persistence of multidrug-resistant and the emer-
gence of extensively drug-resistant Mycobacterium
tuberculosis pose great challenges to public health.3
Community-acquired MRSA clones including
ST59-MRSA-SCCmec type IV-spa type t437, ST30-
MRSA-SCCmec type IV-spa type t019, and ST72-
MRSA-SCCmec type IV-spa type t324 predominate
in Asian countries. Previously established hospital-
acquired MRSA strains including sequence type
(ST)239 and ST5 clones have been found among
community-acquired MRSA isolates from patients
without any risk factors for hospital-acquired MRSA
infection. Community-acquired MRSA clones such
as ST59, ST30, and ST72 have also been isolated
from patients with hospital-acquired infections.5
Various MRSA clones have spread between the
community and hospitals as well as between coun-
tries.5 A few extensively drug-resistant A baumannii
clones have disseminated throughout most hos-
pital settings in Asia.3,4 Even more alarming is
the recent emergence in Taiwan of carbapenem-
resistant Enterobacteriaceae, including those pos-
sessing New Delhi metallo-β-lactamase-1 and 
K pneumoniae carbapenemase.6
Antimicrobial resistance has struck at the core of
infectious disease control worldwide.1,2 Although
antimicrobial-resistant pathogens can be found
throughout the world, antimicrobial resistance is
of particular concern in countries where prescrip-
tion of antimicrobial agents is unregulated and
where antibiotics are widely available over the
counter. The increased use of antibiotics in the
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agriculture and food animal industries is also
consistent with the rise in antimicrobial resis-
tance among human and animal pathogens.1,2
Antimicrobial resistance is also facilitated by the
inappropriate use of medicines, such as taking sub-
standard doses or not finishing a prescribed course
of treatment. Low-quality medicines (generic or
counterfeit drugs), inappropriate prescriptions,
and poor infection prevention and control mea-
sures also contribute to the development and
spread of drug resistance. Lack of government com-
mitment to address these issues, poor nationwide
surveillance, and a diminishing arsenal of tools to
diagnose, treat, and prevent bacterial infections,
also hinder the control of drug resistance.2
On World Health Day 2011, the WHO will
call for action to halt the spread of antimicrobial
resistance by introducing a six-point policy pack-
age to policy-makers and planners, the public
and patients, practitioners and prescribers, phar-
macists and dispensers, and the pharmaceutical
industry worldwide.1,2 The organization strongly
recommends that governments focus control and
prevention efforts in four main areas: (1) surve-
illance of antimicrobial resistance; (2) rational 
antibiotic use; (3) introduction or enforcement 
of legislation related to stopping the selling of 
antibiotics without prescription; and (4) strict
adherence to infection prevention and control
measures, including the use of hand-washing
measures, particularly in healthcare facilities.2
Reversing the trend in antimicrobial resistance
will require continuous survey of resistance data
from clinical isolates from humans as well as
from animals. Effective implementation of an-
tibiotic stewardship programs and strict infec-
tion control policies in healthcare settings are
mandatory.7 Better antibiotic stewardship is needed
to limit the emergence of antibiotic resistance,
prolong the effectiveness of currently available
agents, improve patient outcomes, and reduce
healthcare and societal costs.8 Furthermore, a na-
tional policy should be implemented to limit the
availability of antibiotics in drug stores without
physicians’ prescriptions and also restrict antibiotic
use in animal husbandry. Governments, academic
societies, industries, and patient organizations need
to work together to overcome the increasing threat
of antimicrobial resistance.
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